ABC | Volume 111, Nº6, December 2018

Original Article Radaelli et al Statin treatment in children: meta-analysis Arq Bras Cardiol. 2018; 111(6):810-821 1. Bouhairie, VE, Goldberg A C. Familial hypercholesterolemia. Cardiol Clin. 2015;33(2):169-79. 2. KnipscheerHC,BoelenCC,KasteleinJJ,vanDiemenDE,GroenemeiyerBE,van denEndeA,etal.Short-termefficacyandsafetyofpravastatinin72childrenwith familialhypercholesterolemia.PediatrRes.1996;39(5):867-71. 3. WiegmanA,GiddingSS,WattsGF,ChapmanMJ,GinsbergHN,CuchelM,etal. Familialhypercholesterolaemiainchildrenandadolescents:gainingdecadesof lifebyoptimizingdetectionandtreatment.EurHeartJ.2015;36(36):2425-37. 4. Marks D, Thorogood M, Neil HA, Humphries SE. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis. 2003;168(1):1-14. 5. CelermajerDS,SorensenKE,GoochVM,SpiegelhalterDJ,MillerOI,Sullivan ID, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992;340(8828):1111-5. 6. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta- analysis of data from 90056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78. 7. BelayB,BelamarichPF,Tom-RevzonC.Theuseofstatinsinpediatrics:knowledge base, limitations,andfutuedirections.Pediatrics2007;119(2):370-80. 8. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk ReductioninChildrenandAdolescents;NationalHeart,Lung,andBloodInstitute. Expertpanelonintegratedguidelinesforcardiovascularhealthandriskreduction inchildrenanda dolescents:summaryreport.Pediatrics .2011;128:S213-56. 9. Federal Drug Authority. 2016 [access Feb. 2016]. Available from: http:// www.fda.gov 10. O’Gorman CS, O’Neill M, Conwell L. Considering statins for cholesterol- reduction inchildren if lifest yle and diet changes do not improve their health: a review of the risks and benefits. Vasc Health Risk Manag. 2010;7:1-14. 11. Clauss SB, Holmes KW, Hopkins P, Stein E, ChoM, Tate A, et al. Efficacy and safety of lovastatin therapy in adolescent girls with heterozygous familial hypercholesterolemia. Pediatrics. 2005;116(3):682-8. 12. de Jongh S, Ose L, Szamosi T, Gagné C, Lambert M, Scott R, et al. Efficacy, safety and tolerability of simvastatin in children with familial hypercholesterolaemia: Rationale, design and baseline characteristics. Clin Drug Invest. 2002;22(8):533-40. 13. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010;8:336-41. 14. Robinson KA, Dickersin K. Development of a highly sensitive search strategy for the retrieval of reports of controlled trials using PubMed. Int J Epidemiol. 2002;31(1):150-3. 15. Verzani,John.GettingStartedwithRStudio.California:O’ReillyMedia;2011. 16. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in metaanalyses. BMJ. 2003;327(7414):557-60. 17. McCrindle BW, Ose L, Marias DA. Efficacy and safety of atorvastatin in children and adolescents with familial hypercholesterolemia or severe hyperlipidemia: a multicenter, randomized, placebo-controlled trial. J Pediatr. 2003;143(1):74-80. 18. den Ende A, et al. Short-termefficacy and safety of pravastatin in 72 children with familial hy-percholesterolemia. Pediatr Res. 1996;39(5):867-71. 19. Wiegman A, Hutten BA, de Groot E, Rodenburg J, Bakker HD, Büller HR, et al. Efficacyandsafetyofstatintherapyinchildrenwithfamilialhypercholesterolemia: arandomizedcontrolledtrial.JAMA.2004;292(3):331-7. 20. Rodenburg J, Vissers MN, Wiegman A, Miller ER, Ridker PM, Witztum JL, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol. 2006;47(9):1803-10. 21. Avis HJ, Hutten BA, Gagné C, Langslet G, McCrindle BW, Wiegman A, et al. Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia. J Am Coll Cardiol. 2010;55(11):1121-6. 22. Stein EA1, Illingworth DR, Kwiterovich PO Jr, Liacouras CA, Siimes MA, JacobsonMS, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA 1999;281(2):137-44. 23. van der Graaf A, Cuffie-Jackson C, Vissers MN, Trip MD, Gagné C, Shi G, et al. Efficacy and safety of coadministration of ezetimibe and simvastatin in adolescents with heterozygous familial hypercholesterolemia. J Am Coll Cardiol. 2008;52(17):1421-9. 24. BraamskampMJ, Stefanutti C, Langslet G, Drogari E,Wiegman A, Hounslow N, et al. “Efficacy and safety of pitavastatin in children and adolescents at high future cardiovascular risk.” J Pediatr. 2015;167(2):338-43. 25. Koeijvoets KC, Rodenburg J, Hutten BA, Wiegman A, Kastelein JJ, Sijbrands EJ. Low-density lipoprotein receptor genotype and response to pravastatin in childrenwith familial hypercholesterolemia: substudy of an intima-media thickness trial. Circulation. 2005;112(20):3168-73. 26. Rodenburg J, Vissers MN, Wiegman A, van Trotsenburg AS, van der Graaf A, de Groot E, et al. Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation 2007;116(6):664-8. 27. Ryu SK, Hutten BA, Vissers MN, Wiegman A, Kastelein JJ, Tsimikas S. Lipoprotein-associated phospholipase A2mass and activity in childrenwith heterozygous familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Clin Lipidol 2011;5(1):50-6. 28. Braamskamp MJ, Tsimikas S, Wiegman A, Kastelein JJ, Hutten BA. Statin therapy and secretory phospholipase A(2) in children with heterozygous familial hypercholesterolemia. Atherosclerosis 2013;229(2):404-7. 29. Lambert M, Lupien PJ, Gagné C, Lévy E, Blaichman S, Langlois S, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Pediatrics. 1996;97(5):619-28. 30. LawMR, WaldNJ, Rudnicka AR. Quantifying effect of statins on lowdensity lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. Bmj. 2003;326(7404):1423. 31. Watts GF, Gidding S, Wierzbicki AS, Toth PP, Alonso R, Brown WV, et al. Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation. J Clin Lipidol. 2014;8(3):148-72. 32. Daniels SR, Gidding SS, de Ferranti SD; National Lipid Association Expert Panel on Familial Hypercholesterolemia.. Pediatric aspects of familial hypercholesterolemias: recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011;5(3 Suppl):S30-7. 33. Vuorio A, Kuoppala J, Kovanen PT, Humphries SE, Strandberg T, Tonstad S, et al. Statins for children with familial hypercholesterolemia. Cochrane Database Syst Rev. 2010;7(7):CD006401. 34. Descamps OS, Tenoutasse S, Stephenne X, Gies I, Bealouye V, Lebrethon MC, et al. Management of familial hypercholesterolemia in children and young adults: consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization. Atherosclerosis. 2011;218(2):272-80. 35. Gidding SS, Champagne MA, de Ferranti SD, Defesche J, Ito MK, Knowles JW, et al. The Agenda for Familial Hypercholesterolemia A Scientific Statement From the American Heart Association. Circulation. 2015;132(22):2167-92. 36. Braamskamp MJ, Kusters DM, Wiegman A, Avis HJ, Wijburg FA, Kastelein JJ, et al. Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemiawho had initiated statin therapy in childhood. Atherosclerosis. 2015;241(2):427-32. References 817